Journal
CYTOTHERAPY
Volume 8, Issue 1, Pages 3-12Publisher
ELSEVIER SCI LTD
DOI: 10.1080/14653240500499507
Keywords
AML; CTL; CTLA-4 blockade; DC
Categories
Funding
- PHS HHS [R0131888] Funding Source: Medline
Ask authors/readers for more resources
Background Cells from AML patients can differentiate into the phenotype of DC when cultured with GM-CSF and IL-4. Such cytokine-treated AML-derived DC (AML-DC) can stimulate autologous T cells. In this study we examined whether an anti-CTLA-4 MAb (MDX-010) could enhance the generation of autologous anti-AML T cells. Methods MAb MDX-010 was added to AML PBMC cultures in the presence of GM-CSF and IL-4, a previously reported AML-DC culture method of generating anti-AML T cells. T-cell activation and proliferation were examined thereafter. Results Addition of MDX-010 to GM-CSF/IL-4-conditioned AML-DC cultures induced a mean seven-fold increase in the numbers of autologous T cells compared with cultures without MDX-010 (P < 0.007). T cells stimulated by AML-DC with CTLA-4 blockade were significantly more cytotoxic towards autologous AML cells than those without MDX-010 (42 +/- 23% vs. 26 +/- 15%, E:T ratio of 20). T cells stimulated by AML-DC with CTLA-4 blockade had significantly greater proportions of T cells producing IFN-gamma in response to autologous AML cells than those cultured with AML-DC alone (10.7 +/- 4.7% vs. 4.5 +/- 2.4% for CD4(+) IFN-gamma(+) CD69(+) and 9.8 +/- 4.1% vs. 4 +/- 2.1% for CD8(+) IFN-gamma(+) CD69(+) with or without MDX-010; n = 7; P < 0.007, P < 0.003, respectively). Discussion CTLA-4 blockade enhances the activity and numbers of AML-reactive T cells that can be stimulated by autologous AML-DC and may enhance the efficacy of adoptive immunotherapy of AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available